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ABSTRACT
Pre-exposure prophylaxis (PrEP) for HIV prevention may not only benefit the individual
who uses it, but also their uninfected sexual risk contacts. We developed an agent-based
model using a novel trial emulation approach to quantify disseminated effects of PrEP use
among men who have sex with men in Atlanta, GA. Components (subsets of agents
connected through partnerships in a sexual network, but not sharing sexual partnerships
any other agents) were first randomized to an intervention coverage level or control, then
within intervention components, eligible agents were randomized to PrEP. We estimated
direct and disseminated (indirect) effects using randomization-based estimators and
reported corresponding 95% simulation intervals (SI) across scenarios ranging from 10%
to 90% coverage in the intervention components. A population of 11,245 agents was
simulated for two years, with an average of 1,551 components identified. Comparing agents
randomized to PrEP in 70% coverage components to control agents, there was an 15%
disseminated risk reduction in HIV incidence (95% SI = 0.65, 1.05). Individuals not on PrEP
may receive a protective benefit by being in a sexual network with higher PrEP coverage.
Agent-based models are useful to evaluate possible direct and disseminated effects of HIV
prevention modalities in sexual networks.
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INTRODUCTION
Once daily pre-exposure prophylaxis (PrEP) is a single tablet containing tenofovir
disoproxil fumarate (TDF) and emtricitabine (FTC) that is effective for preventing HIV
transmission among men who have sex with men (MSM) (1, 2). Despite strong evidence of
its effectiveness (3, 4), access to PrEP among MSM remains low, particularly among MSM in
the Southern United States who experience among the highest incidence and prevalence
burdens of HIV infection among all groups in the United States (5-7).
Traditional randomized clinical trials assessing the effect of PrEP use on HIV
incidence only consider the direct (individual) effect of reducing HIV incidence among
individuals who use PrEP. However, PrEP for HIV prevention may not only benefit the
individual user, but also their sexual risk contacts (8). In preventing HIV acquisition among
an individual who uses PrEP, the possibility of secondary transmission to this individual’s
other HIV-uninfected sexual risk contacts and possibly their partners’ partners is also
eliminated (9). This feature (common to other prophylactic therapies such as vaccines) is
referred to as spillover, dissemination, or interference (10, 11). Estimators of the maximal
attainable benefit of an intervention like PrEP, referred to as its composite (total) effect,
should account for both the impact of the intervention on its users, as well as the impact of
the intervention on individuals who did not use the intervention themselves, but were
connected to users.
In causal inference methodology, a fundamental assumption of much work is the
stable unit treatment value assumption (SUTVA) (12), which includes an assumption of no
dissemination, or interference, between individuals. An assumption of no dissemination
requires that the potential outcomes of one individual be unaffected by the treatment or
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intervention assignment of other individuals. Both effects are readily identifiable in twostage randomized trials (Figure 1) (10, 13), where randomization first occurs at a group
level (i.e., groups of connected individuals are randomly assigned to an intervention
allocation strategy or control) and then at an individual level (i.e., individuals are assigned
to receive an intervention or not according to their group allocation strategy) (Figure 2).
The disseminated (indirect) effect of the intervention is defined as the effect of being in an
intervention group and randomized to not receive an intervention versus being in a control
group.
We adapted a previously published agent-based model (ABM) (14, 15), simulating
HIV transmission in a hypothetical population of MSM in Atlanta, GA, USA (16, 17), to
emulate a two-stage randomized clinical trial (18), which may be considered unfeasible or
currently unethical to implement in this population, as PrEP is currently FDA-approved for
HIV prevention and often used as an active control in studies of ‘next generation’ HIV
prevention modalities (19). We selected the city of Atlanta, GA as a case study because of
the high HIV incidence and prevalence among MSM in this setting (20). Access to PrEP
could be improved in this population and benchmarks for coverage could be used to inform
and expedite efforts to end the HIV epidemic in the Southeastern United States (21). We
aim to evaluate the magnitude and direction of possible disseminated effects of PrEP use
among MSM in Atlanta, GA.
METHODS
Model Setting
We adapted a previously published model of PrEP uptake and HIV transmission
among MSM in Atlanta and complete details about this model can be found in (14). We
5

employed a discrete-time, stochastic, agent-based model to simulate a two-stage
randomized trial of PrEP for HIV prevention in a population of MSM (aged 18-65 years) in
Atlanta, GA, USA and followed agents for two years from 2015 to 2017 (14, 22). Each agent
in the model was assigned characteristics related to demographic, behavioral, HIV status,
and clinical status. The simulated agent population was 51% African American. Aligning
with empirical estimates (20, 23, 24), we assumed that, among African American agents,
the median age was 32 years, 30% were using substances, 32% had a preferred receptive
sexual role, and 24% had a preferred insertive sexual role. Among white non-Hispanic
agents, we assumed that the median age was 35 years, 49% were using substances, 23%
had a preferred receptive sexual role, and 23% had a preferred insertive sexual role.
Whenever possible, each individual agent’s behaviors and characteristics were
parameterized based on empirical estimates from the study setting. Several parameter
values (e.g., those governing initial HIV prevalence and treatment) were stratified by race
(14), reflecting the substantial racial/ethnic disparities in HIV incidence and prevalence in
this setting (20).
The model simulated a dynamic population with 1,000 total simulations per
scenario, where the scenarios corresponded to a series of two-stage randomized trials.
Because this ABM was simulating a randomized trial with a short duration of follow-up,
agents and their characteristics were generated in a base population and no new agents
were allowed to enter the population. Python (version 2.7.12) was used for coding, testing
and performing sensitivity analyses of this model and R (Version 3.5.1) was used to analyze
the model output. Additional information regarding parameter values, key model
assumptions, and data sources are included in the Supplemental Appendix.
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Sexual Networking and Components
Prior to “enrollment” (i.e., model initialization) in the hypothetical trial, agents
formed sexual partnerships to create a sexual network of many distinct components. A
sexual network component was defined as a subset of the agents in a network that are all
connected through at least one partnership and not connected to any other agents in the
network. After two-stage randomization, where components were first randomized to an
intervention allocation strategy, then within each component, agents were randomized
according to that strategy, annual number of partners and number of sex acts were
assumed to follow stochastic distributions with parameters based on the literature (20,
25). At discrete time-steps (measured in months since randomization) over the two years
of follow-up, relationships were not dissolved and new relationships were not formed, but
rather sexual networks were assumed to be static, as ascertained prior to enrollment in the
trial. This is akin to a randomized trial design, where often the sexual networks are
ascertained only once at the start of the study (26, 27). These partnerships at enrollment
were used to determine network components of size 2 to 100 agents.
HIV Transmission, Treatment and Progression
Detailed HIV transmission, treatment, and disease progression processes and
parameters have been described in detail previously (14, 15). At each monthly interval,
agents had a certain number of sex acts with their partners. The probability of condom use
was lower if the agent used substances and also decreased as a function of the number of
prior contacts with a given partner. In the absence of any biomedical intervention (PrEP or
treatment as prevention, known as TasP), any condomless sex act in a serodiscordant
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partnership had a non-zero probability of HIV transmission (per-act probability for
condomless receptive anal intercourse was 1.38% and insertive was 0.11%) (28). This
probability varied depending upon the following factors: if the HIV-negative agent was
randomized to PrEP; among HIV-negative agents randomized to PrEP, their adherence to
PrEP; and among HIV-infected agents, knowledge of their HIV status, HIV treatment, and if
they achieved viral suppression after initiation of HIV treatment.
Impact of Substance Use on Agent Behavior
We included an agent class characterized by substance use, which was defined at
model initialization and remained stable for the duration of the study. The prevalence of
substance use, defined as any drug use, was set to 30% among African Americans and
48.5% among whites (20, 23). In the model, substance use influenced PrEP adherence,
condomless sex, and assortative mixing in sexual partner selection. Agents who were
defined as substance users had a 35% lower probability of achieving optimal adherence to
PrEP (8), and a 20% higher probability of engaging in condomless sex (29). In addition, we
assumed that 20% of substance using agents mix with other substance using agents.
Oral Pre-Exposure Prophylaxis (PrEP) Use and HIV Treatment
After enrollment in the hypothetical trial, eligible agents who were randomized to the PrEP
intervention were assumed to continue to receive PrEP for the two-year duration of the
trial. For the two-year duration of this simulated trial, all agents were retained in the study
and no agents died. At enrollment in the trial, agents were classified as optimally adherent
to PrEP (defined as 4 or more doses per week), or were sub-optimally adherent (defined as
2 to 4 doses per week). Those with optimal adherence had a 96% reduction in the per-act
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probability of HIV acquisition, while those with partial adherence had only a 76%
reduction (30). Agents on ART were less likely to progress to AIDS than other HIV-infected
agents. This was achieved through a scalar reduction in profession probability, with the
reduction dependent on ART adherence (31, 32).
Simulated Trial Design
The current study simulated a two-stage randomized trial (Figure 2). In the first stage,
network components were randomized 1:1 to either receive a certain PrEP coverage
(referred to as “intervention components) or no PrEP coverage (referred to as “control
components) (18, 33). PrEP coverage level was defined as the proportion of eligible agents
receiving PrEP in a component, where eligible agents were defined as those who were HIVnegative with one or more partnerships and ages 18 to 65 years old at enrollment. PrEP
coverage was assigned at baseline. We assumed that agents assigned to PrEP take at
minimum two or more doses per week with adherence pattern remained stable for the
duration of follow-up. We assumed that PrEP adherence did not change PrEP coverage
following an intention-to-treat approach and that PrEP coverage generally remained stable
during follow-up. HIV-negative agents in each intervention component were randomized to
PrEP according to the assigned coverage level. We consider the following scenarios: PrEP
coverage level (in each component) of 10% to 90%, in increments of 10%.
At the baseline visit of the trial, agents who were randomized to PrEP initiated their
intervention and all agents, regardless of HIV status, were followed for two years to
ascertain their HIV status. We assumed no drop out (i.e., 100% retention on PrEP over the
two years of follow-up). We also assumed over the two years that the probability of death
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is zero, which may be reasonable given the age range of agents and short duration of
follow-up.
Causal Inference Methods for Evaluation of Dissemination using ABMs
Several assumptions are needed to identify causal effects in the presence of
dissemination. We assumed partial interference (13); that is, the intervention assignment
affects the outcomes of other agents in the same component only, but does not extend to
other agents outside their component. We also assumed stratified interference, in which an
agent’s potential outcome is dependent only on their own intervention assignment and the
proportion of those randomized to the intervention in their component (34). We also make
the usual assumptions required for causal inference (exchangeability, consistency, and
positivity) (35). Due to randomization at both the component- and agent-level, marginal
exchangeability holds: Components randomized to the intervention will be, on average,
comparable to components randomized to the control. Furthermore, within each
component, agents randomized to the intervention will be, on average, comparable to
agents randomized to the control. Positivity means that there is a non-zero probability of
exposure within each level of the covariates (36, 37). We assumed an independent
Bernoulli allocation strategy for intervention assignment within each intervention
component (13).
In our simulated trial, the sexual risk component sizes vary, so we employed estimators
that account for varying component size (38). Assume there are 𝐼 components and each of
the component has 𝑛𝑖 individuals indexed by 𝑗 = 1,2, . . . , 𝑛𝑖 and ∑𝐼𝑖=1 𝑛𝑖 = 𝑁. Let 𝑌𝑖𝑗 ,
𝐴𝑖𝑗 represent an observed outcome and intervention assignment status of 𝑗𝑡ℎ agent in
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component 𝑖. In addition, 𝐶𝑖 denotes the intervention assignment strategy at the
component level that corresponds to intervention coverage denoted by 𝛼, where 𝐶𝑖 = 1 if
the intervention allocation strategy was 𝛼 and 𝐶𝑖 = 0, otherwise. Let 𝐴(𝑛) be the set of
vectors of all possible exposure allocations of length 𝑛. We consider the potential outcome
for agent 𝑗 in component 𝑖 as 𝑌𝑖𝑗 (𝐶𝑖 = 𝑐, 𝐴𝑖𝑗 = 𝑎). Because we have a “pure control group”,
there are three possible combinations of the following potential outcomes:
𝑌𝑖𝑗 (1,1), 𝑌𝑖𝑗 (1,0), 𝑌𝑖𝑗 (0,0). By (causal) consistency (39-41), the observed outcome is a
function of the intervention assignment and potential outcomes; that is, 𝑌𝑖𝑗𝑜𝑏𝑠 =
𝐶𝑖 𝐴𝑖𝑗 𝑌𝑖𝑗 (1,1) + 𝐶𝑖 (1 − 𝐴𝑖𝑗 )𝑌𝑖𝑗 (1,0) + (1 − 𝐶𝑖 )𝑌𝑖𝑗 (0,0). Let 𝑇𝑐𝑎 = {(𝑖, 𝑗): 𝐶𝑖 = 𝑐 𝑎𝑛𝑑 𝐴𝑖𝑗 =
𝑎} to denote the set of components and agents who are assigned to 𝐶𝑖 = 𝑐 and 𝐴𝑖𝑗 = 𝑎.
In the setting with varying component sizes, there are two types of estimands:
component-weighted estimands that assign equal weight to components, regardless of the
number of individuals in each component; and agent-weighted estimands that assign equal
weight to agents, regardless of the distribution across components. The direct (i.e.,
individual) effect measures the additional benefit of being on PrEP beyond being in an
intervention component with a fixed PrEP coverage level (Figure 1) and is defined as
𝑛

𝑖
𝐷𝐸 = ∑𝐼𝑖=1 𝑤𝑖∗ ∑𝑗=1
[𝑌𝑖𝑗 (1,1) − 𝑌𝑖𝑗 (1,0)] ;

The disseminated (i.e., indirect) effect compares those who were not on PrEP themselves
and in an intervention component, to those who were in a control component and is
defined as
𝑛

𝑖
𝐼𝐸 = ∑𝐼𝑖=1 𝑤𝑖∗ ∑𝑗=1
[𝑌𝑖𝑗 (1,0) − 𝑌𝑖𝑗 (0,0)] ;
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The composite (i.e., total) effect is the combined direct and disseminated effect and is
defined as
𝑛

𝑖
𝑇𝐸 = ∑𝐼𝑖=1 𝑤𝑖∗ ∑𝑗=1
[𝑌𝑖𝑗 (1,1) − 𝑌𝑖𝑗 (0,0)] ;

The overall effect marginalizes over the agent exposure and compares intervention to
control components; that is,
𝑛

𝑖
𝑂𝐸 = ∑𝐼𝑖=1 𝑤𝑖∗ ∑𝑗=1
[𝑌𝑖𝑗 (1,⋅) − 𝑌𝑖𝑗 (0,⋅)],

1

1

where 𝑤𝑖∗ = 𝐼𝑛 corresponds to component-weighted estimands and 𝑤𝑖∗ = 𝑁 corresponds to
𝑖

agent-weighted estimands with 𝑁 = ∑𝑛𝑖 .
To quantify these estimands, we employ the two-stage inverse probability weights
𝑤𝑖 (0) , 𝑤𝑖 (10) , 𝑤𝑖 (11) as 𝑤𝑖 (11) =

1

1

, 𝑤𝑖 (10) =

𝑃𝑟(𝐶𝑖 =1) 𝑃𝑟(𝐴𝑖𝑗 =1|𝐶𝑖 =1)

1

1

𝑖

𝑖

1

1

, and

𝑃𝑟(𝐶𝑖 =1) 𝑃𝑟(𝐴𝑖𝑗 =0|𝐶𝑖 =1)

𝑤𝑖 (0) = 𝑃𝑟(𝐶 =0). Define 𝑤𝑖 (𝑐) = 𝑃𝑟(𝐶 =𝑐). The weighted direct, disseminated, composite, and
overall effect estimators are
̂ = ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (11) 𝑌𝑖𝑗𝑜𝑏𝑠 (1,1) − ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (10) 𝑌𝑖𝑗𝑜𝑏𝑠 (1,0),
𝐷𝐸
11
10

̂ = ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (10) 𝑌𝑖𝑗𝑜𝑏𝑠 (1,0) − ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (0) 𝑌𝑖𝑗𝑜𝑏𝑠 (0,0),
𝐼𝐸
10
00

̂ = ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (11) 𝑌𝑖𝑗𝑜𝑏𝑠 (1,1) − ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (0) 𝑌𝑖𝑗𝑜𝑏𝑠 (0,0),
𝑇𝐸
11
00

̂ = ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (1) 𝑌𝑖𝑗𝑜𝑏𝑠 (1,⋅) − ∑(𝑖,𝑗)∈𝑇 𝑤𝑖∗ 𝑤𝑖 (0) 𝑌𝑖𝑗𝑜𝑏𝑠 (0,⋅).
𝑂𝐸
1⋅
0⋅
For example, the estimator of the disseminated effect is the weighted average of the
outcomes among agents assigned to no PrEP in intervention components minus the
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weighted average of the outcomes among agents in control components (Figure 1). These
estimators are unbiased in a two-stage randomized design (12).
Outcome Measures
The primary outcome measure was cumulative HIV incidence over 24 months after
randomization in the simulated trial. We examined the estimated HIV incidence for each
component PrEP coverage level among the intervention group, separately for agents on
PrEP and agents not on PrEP. These parameters were computed using nonparametric
estimators, as described above, along with 95% simulation intervals (i.e., credible
intervals) given the stochastic framework of these models (i.e., middle 95% of simulated
output) (42). Comparisons were made between the intervention agents and control agents
within each simulated trial and across trials comparing various intervention coverage
levels.
Sensitivity Analyses
Because we are evaluating disseminated effects, the results may depend on not only the
efficacy of PrEP, but also the number and probability of sexual partnerships, as well as the
size of the components. We performed one-way sensitivity analyses to evaluate the impact
of modifying adherence to PrEP and maximum PrEP efficacy to prevent HIV (see
Supplemental Appendix). Specifically, we assessed the following: probability of
partnership, baseline number of sexual acts, adherence to PrEP, efficacy of PrEP for
suboptimal adherence, and maximum component size. We also performed a sensitivity
analysis excluding the substance use agent class.
RESULTS
13

There were 11,245 agents in the simulated population, followed from 2015 to 2017 with an
average of 1,551 components identified in each iteration of the model. At enrollment in the
entire simulated trial with 70% PrEP coverage, the HIV point prevalence was 29% (95%
simulation interval (SI) = 27%, 30%). The majority of components (48%) had low HIV
prevalence (< 5%), while 26% had higher HIV prevalence (45% to 50%) at enrollment.
Although our model considered a range of intervention coverage levels (Table 1), we
focused the discussion of results on two simulated trial designs that provide insights into
two strategies: (1) intervention components with lower (30%) PrEP coverage and (2)
intervention components with higher (70%) PrEP coverage.
We first report the average results from simulated trials with 30% coverage in the
intervention components (Table 2). Within intervention components, there was an
estimated 82% direct risk reduction in cumulative HIV incidence among agents on PrEP
compared to agents not on PrEP (Risk Ratio (RR) = 0.18, 95% SI: 0.13, 0.24). Comparing
agents not on PrEP within intervention components to agents within control components,
the estimated disseminated effect was an estimated 8% risk reduction (RR = 0.92, 95% SI:
0.79, 1.06). The estimated composite (combined direct and disseminated) effect was an
estimated 83% risk reduction (RR = 0.17, 95% CI: 0.11, 0.22). Comparing agents within
intervention components to those within control components, marginalizing over
individual-level PrEP use, there was an estimated 30% reduction in the overall risk (RR =
0.70, 95% SI: 0.60, 0.80).
We then report the average results from simulated trials with 70% coverage in the
intervention components (Table 2). The estimated direct effect was an 83% reduction (RR
= 0.17, 95% SI = 0.13, 0.23) in cumulative HIV incidence among agents on PrEP compared
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to agents not on PrEP within intervention components. The estimated disseminated effect
was a 15% reduction (RR = 0.85, 95% SI = 0.65, 1.05) in cumulative HIV incidence, which
means that agents not on PrEP in the intervention group had lower cumulative HIV
incidence, as compared to control agents. The estimated composite effect was an 85%
reduction in the cumulative incidence of HIV, comparing agents on PrEP within
intervention components to agents within control components (RR = 0.15, 95% SI = 0.11,
0.20). Comparing agents within intervention components to those within control
components, there was an estimated 65% reduction in the overall effect (RR = 0.35, 95%
SI: 0.28, 0.42).
Figure 3 displays the estimated direct and disseminated risk difference and risk
ratio effects on cumulative incidence of HIV as a function of component PrEP coverage with
95% simulation intervals. As the intervention coverage increases in a component, the
estimated direct effect is attenuated towards the null, although this trend is more apparent
on the difference scale. On the other hand, when the intervention coverage is increased in a
component, the estimated disseminated effect increased in magnitude on both the
difference and ratio scale.
We performed one-way sensitivity analyses to assess the impact of our model
parameterization on the results, specifically cumulative HIV incidence over two years. In
Table S8 and S9 (see Supplemental Appendix), we display the HIV prevalence and
cumulative incidence at the end of two years of follow-up after randomization based on a
simulated trial with 30% and 70% coverage, respectively. The number of incident HIV
infections among agents in the base case was typically between the estimates for the
scenarios with the parameters either half or double the base case, except for annual sexual
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partnerships. In a sensitivity analysis excluding the substance use agent class, the
disseminated effect was stronger for 30% coverage trials (RD = -0.02 and RR = 0.65) and
70% coverage trials (RD = -0.03 and RR = 0.24) (Table S4 to S7). The linear trends of the
effects on the difference scale across increasing coverage levels were more visually
apparent (Figure S2 to S3). We also displayed the estimated effects across the one-way
sensitivity analysis (Tables S10 and S11, Figures S4 to S7). The estimated effects were
typically attenuated towards the null on the difference scale and away from the null on the
ratio scale.

DISCUSSION
We employed an ABM to simulate an idealized two-stage randomized trial to evaluate the
direct and disseminated effects of PrEP among MSM in Atlanta (14). We observed
disseminated effects of PrEP among those not randomized to PrEP, but who shared a sexual
risk network component with agents randomized to PrEP (with up to a 15% reduction in
cumulative HIV incidence at coverage level 70%). We found that increasing PrEP coverage
levels in a component strengthens the disseminated effect on reducing HIV incidence
among those who were not randomized to the intervention; however, increasing PrEP
coverage also possibly weakens the direct effect among those who were randomized to the
intervention on the difference scale only. In other words, the individual benefit of receiving
PrEP depends on the coverage of PrEP in an individual’s network: the higher the
proportion of one’s sexual partners is on PrEP, the smaller the absolute direct, additional
individual benefit of therapy beyond being in an intervention component. This type of
simulation study can help to inform PrEP coverage levels needed to reduce HIV incidence
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below a targeted threshold, while considering the complex sexual risk networks in which
MSMs are embedded, as well as considering related risk factors, such as substance use.
Many evaluations of the efficacy and effectiveness of PrEP focus on overall effect
without consideration of the sexual risk network in which these individuals are embedded
(43). Many of these studies are individually-randomized designs and often lack inference
regarding the influence of others in the sexual network component or study cluster. Overall
effects depend on spurious features of the study design, including the size of the
components and PrEP coverage in each component. Therefore, it will likely not be
generalizable from one study to the next or to any scaled-up population, unless these
features remain constant (44). In this ABM, we observed many scenarios contrasting
adjacent coverage levels for which the overall effect estimate was closer to the null, while
the composite effect demonstrated a more protective effect, highlighting the importance of
considering the suite of disseminated and direct effects when dissemination may be
present.
There are several strengths to this approach. As it would be unethical and likely
unfeasible to conduct a two-stage randomized trial in this population, this ABM-based
approach provides insights about the direction and magnitude of these various effects.
Furthermore, we can run numerous simulated trials with different coverage PrEP levels to
better understand the impact on population-level HIV incidence. To the best of our
knowledge, this is the first paper to assess causal disseminated effects in the context of an
ABM and offers additional insight on how to leverage causal inference methodology to
improve the inference gleaned from simulation-based techniques.
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This particular agent-based modeling approach has several limitations. We made
strong assumptions, such as static sexual networks and 100% retention in care during the
two years of study follow-up. Assuming static components in the sexual networks does not
accurately reflect the underlying true sexual network; however, if we allow the sexual
networks to vary over time, there could be a violation of the partial interference or the
stratified interference assumptions. Future methods work is needed to develop
appropriate methods for interference structures that change over time. Randomized trials,
as well as two-stage randomized trials, are subject to Hawthorne effects, and may not
actually represent the patient experience in medical care. Unfortunately, there are no twostaged randomized trials of PrEP to compare and contrast our model results; however,
further comparisons to trial-based estimates of HIV prevalence and incidence could help to
improve the model to simulate more realistic scenarios that emulate a real-world trial.
In future work, we will evaluate possible effect modification by component-level
characteristics, such as HIV prevalence, racial distribution, and substance use prevalence,
and this information can be used to better allocate resources. We will also extend our
approach for other study design settings, including cluster-randomized trials and
observational cohort studies. When the design requires adjustment for confounding at
either the agent and/or component levels, we will triangulate this approach with a gformula approach in the context of dissemination (45, 46). Future work could also compare
different counterfactual definitions in agent-based models, including simulating potential
outcomes at the component level. Individuals not on PrEP may benefit by being in a sexual
network with higher PrEP coverage levels.
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ABMs are useful to evaluate potential direct and disseminated effects of HIV
prevention modalities in complex sexual networks among men who have sex with men.
Employment of these models can provide more timely information about the most
impactful ways to increase PrEP access, particularly among those underserved in the
Southern United States.

19

Tables and Figures
Table 1. Cumulative incidence of HIV over two years of follow-up after two-stage randomization among agents within PrEP
intervention and control components with 95% simulation intervals (SI) in an agent-based model representing among men
who have sex with men Atlanta, Georgia, 2015-2017 (n = 11,245)
Agents on PrEP

Agents Not on PrEP

Control Agents

Component PrEP
Coverage Level,%

Total
Persons

HIV+

Cumulative
Incidence

Total
Persons

HIV+

Cumulative
Incidence

Total
Persons

HIV+

Cumulative
Incidence

10

396.94

17.4

0.044

3098.96

711.5

0.230

4095.03

894.3

0.137

20

771.12

32.27

0.042

3113.59

612.65

0.197

4091.70

895.05

0.138

30

1163.53

44.3

0.038

3109.28

519.21

0.167

4100.73

897.47

0.138

40

1572.93 59.07

0.038

3115.15

432.86

0.139

4096.74

893.14

0.137

50

1967.04 68.08

0.035

3106.68

339.58

0.109

4093.03

885.55

0.136

60

2395.52

77.5

0.032

3117.22

257.92

0.083

4083.12

884.76

0.136

70

2806.26 84.92

0.030

3141.71

183.82

0.059

4065.79

871.33

0.135

80

3177.9

91.83

0.029

3139.32

120.57

0.038

4037.26

874.74

0.136

90

3612.07

97.8

0.027

3146.35

50.31

0.013

4031.51

871.25

0.136
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Table 2. Effects of PrEP on cumulative incidence of HIV over two years of follow-up after
two-stage randomization among agents within PrEP intervention and control components
with 95% simulation intervals (SI) in an agent-based model representing men who have
sex with men, Atlanta, Georgia, 2015-2017 (n = 11,245)1

Effect

RD

95% SI

RR

95% SI

Direct

-0.05

-0.06, -0.04

0.18

0.13, 0.24

Disseminated

-0.01

-0.01, 0.00

0.92

0.79, 1.06

Composite

-0.06

-0.06, -0.05

0.17

0.11, 0.22

Overall

-0.02

-0.03, -0.01

0.70

0.60, 0.80

Direct

-0.05

-0.06, -0.04

0.17

0.13, 0.23

Disseminated

-0.01

-0.02, 0.00

0.85

0.65, 1.05

Composite

-0.06

-0.06, -0.05

0.15

0.11, 0.20

Overall

-0.04

-0.05, -0.04

0.35

0.28, 0.42

30% Coverage

70% Coverage

1 RD

= Risk Difference; RR = Risk Ratio.
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Figure 1: Types of causal effects in the context of dissemination (or interference) in twostage randomized designs of a pre-exposure prophylaxis (PrEP) intervention in an agentbased model representing men who have sex with men, Atlanta, Georgia, 2015-2017 (17).
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Figure 2: Two-stage randomized design to evaluate PrEP for HIV prevention in a population
of MSM. Trial 1 corresponds to a PrEP allocation strategy with 33% coverage in intervention
components. Trial 2 corresponds to a PrEP allocation strategy with 66% coverage in
intervention components.

Trial 1

Trial 2

Ascertainment of
components in
sexual network

First stage of
randomization

Interv. Cov = 33%

Control

Interv. Cov = 66%

Control

Second stage of
randomization
among eligible

33% randomized to
intervention

0% randomized to
intervention

66% randomized to
intervention

0% randomized to
intervention

HIV-Positive Agent
HIV-Negative Agent, no PrEP
HIV-Negative Agent, PrEP
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Figure 3. Estimated (a) direct risk difference effects (b) disseminated risk difference effects
(c) direct risk ratio effects (d) disseminated risk ratio effects of PrEP on cumulative
incidence of HIV as a function of component PrEP coverage with 95% simulation intervals in
two-stage randomized designs of a pre-exposure prophylaxis (PrEP) intervention in an
agent-based model representing men who have sex with men, Atlanta, Georgia, 2015-2017
(a)

(b)

(c)

(d)
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